Licence extension submission accepted for kidney disease treatment by EMA
The licence extension submission for Invokana and Vokanamet has been accepted by the EMA.
List view / Grid view
The licence extension submission for Invokana and Vokanamet has been accepted by the EMA.
Two companies will work closely together on future development, distribution, promotion, access, marketing and sales of Invokana (canagliflozin) for type 2 diabetes...